Free tool
FAERS Monitor: Brenzavvy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214373 or its brand name (Brenzavvy, Bexagliflozin). Reports on generic versions are filed under their own applications.
Reports
31
Serious
12
39% of reports
Hospitalization
3
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache7
- weight decreased7
- fatigue6
- nausea6
- cough5
- decreased appetite5
- asthenia4
- chest discomfort4
- dyspnoea4
- gastrointestinal disorder4
- oropharyngeal pain4
- throat irritation4
- throat tightness4
- abdominal pain upper3
- blood glucose increased3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 14 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| throat tightnessSignal | 4 | 100.4 | 40.2 | 301 |
| throat irritationSignal | 4 | 60.5 | 24.2 | 179 |
| gastrointestinal disorderSignal | 4 | 30.3 | 12.1 | 86 |
| oropharyngeal painSignal | 4 | 29.3 | 11.7 | 83 |
| chest discomfortSignal | 4 | 26.5 | 10.6 | 75 |
| weight decreasedSignal | 7 | 17.0 | 8.9 | 91 |
| decreased appetiteSignal | 5 | 14.6 | 6.5 | 51 |
| coughSignal | 5 | 12.1 | 5.4 | 41 |
| blood glucose increasedSignal | 3 | 10.8 | 3.7 | 18 |
| abdominal pain upperSignal | 3 | 9.9 | 3.4 | 16 |
| headacheSignal | 7 | 7.6 | 3.9 | 35 |
| astheniaSignal | 4 | 7.2 | 2.9 | 16 |
| fatigueSignal | 6 | 5.2 | 2.5 | 17 |
| nauseaSignal | 6 | 5.1 | 2.5 | 17 |
| dyspnoeaSignal | 4 | 4.8 | 1.9 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.